Medigene AG: Poster presentations at AACR 2021 Annual Meeting

Medigene AG: Poster presentations at AACR 2021 Annual Meeting

Planegg/Martinsried (pta/10.03.2021/22:35) Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present two posters at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2021 being held on 10-15 April 2021.

The work relates to two of Medigene's preclinical research programs including the collaborative project with the Université de Montréal evaluating T cell responses to tumor-specific target antigens derived from non-coding regions of the genome and another project focused on the in vitro and in vivo anti-tumor activity of T cells carrying a PRAME-specific T cell receptor (TCR) and the PD1-41BB switch receptor.

The full-length abstracts for the research to be presented at the meeting have been published online today at https://www.aacr.org/meeting/aacr-annual-meeting-2021/abstracts/ and posters will be available online on 10 April 2021.

Poster details
#1520 Targetable immunogenic tumor specific antigens can be identified in non-coding regions of the genome
Tiziana Franceschetti, Qingchuan Zhao, Krystel Vincent, Claude Perreault, Slavoljub Milosevic, and Daniel Sommermeyer
Session details: Immunology; Adoptive Cell Therapy; E-Poster

#1521 Combining a PRAME-specific TCR showing potent in vitro and in vivo anti-tumor reactivity and a favorable preclinical safety profile with a PD1-41BB switch receptor results in highly efficient T cells
Ina Fetzer, Nadja Sailer, Melanie Salvermoser, Manon Weis, Christian Krendl, Maja Bürdek, Doris Brechtefeld, Isabella Rampp, Julian Rydzek-Wiesner, Monika Braun, Christian Ellinger, Christiane Geiger, Daniel Sommermeyer, Susanne Wilde
Session details: Immunology; Adoptive Cell Therapy; E-Poster